 "SPARC licenses Xelpros to Sun Pharma; stock gains 5%")
Shares of Sun Pharma Advanced Reseasrch Company ( SPARC) are trading higher by 5% to Rs 426 on the BSE after the company licensed out Xelpros (Latanoprost BAK-free eye drops) to a subsidiary of Sun Pharma for the US market.
Apart from the advance payment of $3 million, SPARC will receive certain other payments, both summing up to a total of $16 million from Sun Pharma. Further, it is also eligible for certain defined royalties and additional payments associated to the actual sales performance of Xelpros.
Anil Raghavan, CEO, SPARC said, “SPARC is excited at this licensing deal for Xelpros because it allows us to commercialize the first-class science we've been doing at our research labs. Xelpros is a much safer product that greatly improves the standards of glaucoma care."
SPARC opened at Rs 424 and touched a high of Rs 438 on the BSE. Meanwhile, Sun Pharma opened at Rs 813 and touched a high of Rs 828 on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%